NCT02953678 2021-11-24A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1)Incyte CorporationPhase 2 Completed71 enrolled 24 charts 1 FDA